Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Aintzane Zabaleta, Noemi Puig, Maria Teresa Cedena Romero, Jose J Perez, Cristina Moreno, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Veronica Gonzalez-Calle, Lucia Lopez Corral, Beatriz Rey-Búa, Borja Puertas Martínez, Fatima Miras, Jose Sanchez-Pina, Nieves Lopez, Joaquin Martinez-Lopez, Maria Victoria Mateos, Jesus San-Miguel, Bruno Paiva

Blood (2023) 142 (Supplement 1): 94.

https://doi.org/10.1182/blood-2023-185980

Published: 2023

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Blood (2021) 138 (Supplement 1): 76.

https://doi.org/10.1182/blood-2021-146535

Published: 2021

Journal Articles

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136258

Published: 2020

Journal Articles

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

Blood (2020) 135 (26): 2375–2387.

https://doi.org/10.1182/blood.2019003382

Published: 2020

Includes: Supplemental data

Journal Articles

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 509.

https://doi.org/10.1182/blood-2019-128049

Published: 2019

Journal Articles

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 581.

https://doi.org/10.1182/blood-2019-127717

Published: 2019

Journal Articles

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 1852.

https://doi.org/10.1182/blood-2019-128655

Published: 2019

Journal Articles

Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM)

Blood (2018) 132 (Supplement 1): 3170.

https://doi.org/10.1182/blood-2018-99-119281

Published: 2018

Journal Articles

Immune Predictors of Response to Pembrolizumab Monotherapy As Consolidation in Multiple Myeloma Patients: Results of the GEM-Pembresid Clinical Trial

Enrique M. Ocio, MDPhD, Noemi Puig, MD PhD, Luis Corchete, José J Pérez, Julio Dávila, Teresa Paíno, Javier de la Rubia, Albert Oriol, MD, Jesús Martín, Felipe De Arriba, PhD, Joan Bladé, MD PhD, M Jesús Blanchard, Ramón García-Sanz, MD, Bruno Paiva, PhD, Juan-José Lahuerta, Jesus F. San Miguel, MD, Maria-Victoria Mateos, MD

Blood (2017) 130 (Supplement 1): 1874.

https://doi.org/10.1182/blood.V130.Suppl_1.1874.1874

Published: 2017

Journal Articles

Peripheral Blood Analysis By Flow Cytometry for the Diagnosis of Type I Chronic Myelomonocytic Leukemia

Blood (2015) 126 (23): 5248.

https://doi.org/10.1182/blood.V126.23.5248.5248

Published: 2015

Journal Articles

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

Juan A Flores-Montero, MD, Bruno Paiva, PhD, Luzalba Sanoja-Flores, M.Sc., Noemi Puig, MD PhD, Omar García, PhD, Sebastian Böttcher, MD PD, José J Pérez-Morán, Maria Belen Vidriales, MD PhD, Maria-Victoria Mateos, Ramon Garcia-Sanz, MD PhD, Cristina Jimenez, BsC, Marcos González, MD PhD, Joaquin Martinez-López, MD PhD, María Consuelo Cañizo, MD PhD, Jesus San Miguel, MD PhD, Brian Durie, MD, Jacques J.M. van Dongen, Alberto Orfao, MD PhD

Blood (2015) 126 (23): 367.

https://doi.org/10.1182/blood.V126.23.367.367

Published: 2015

Journal Articles

PD-1 and PD-L1 Are Overexpressed in the "Intermediate CD14+CD16+" and "Non Classical CD14lowCD16+" but Not in the "Classical CD14+CD16-" Monocytes in the Peripheral Blood of Chronic Myelomonocytic Leukemia

Hae Tha Mya, MRCP, FRCPath, Maria Diez Campelo, MD PhD, Sandra Valle Herrero, MD, Agustin Díaz-Alvarez, MDPhD, Domingo Bustos, MD, Luis M Vaquero, MD, José J Pérez, Verónica González, MD, Jose M Bastida, MD, Carlos Aguilar, MD, Abelardo Bárez, MD, Noemi Puig, MD PhD, Alejandro Martin-Sancho, MD PhD, María Jesús Garcia, Irene Aires, Sara Alonso, MD, Marcos González, MD PhD, Consuelo Del Cañizo, MD PhD, Maria Belen Vidriales, MD PhD

Blood (2015) 126 (23): 1694.

https://doi.org/10.1182/blood.V126.23.1694.1694

Published: 2015

Journal Articles

The cellular origin and malignant transformation of Waldenström macroglobulinemia

Blood (2015) 125 (15): 2370–2380.

https://doi.org/10.1182/blood-2014-09-602565

Published: 2015

Includes: Supplemental data

Journal Articles

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Blood (2012) 120 (21): 3949.

https://doi.org/10.1182/blood.V120.21.3949.3949

Published: 2012

Journal Articles

Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,

Blood (2011) 118 (21): 3936.

https://doi.org/10.1182/blood.V118.21.3936.3936

Published: 2011

Journal Articles

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

Blood (2011) 118 (21): 3938.

https://doi.org/10.1182/blood.V118.21.3938.3938

Published: 2011

Journal Articles

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

Bruno Paiva, María-Belén Vídriales, José J. Pérez, María-Consuelo López-Berges, Ramón García-Sanz, Enrique M. Ocio, Natalia de las Heras, Rebeca Cuello, Alfonso García de Coca, Emilia Pardal, José Alonso, Magdalena Sierra, Abelardo Bárez, José Hernández, Lissbett Suárez, Josefina Galende, María-Victoria Mateos, Jesús F. San Miguel

Blood (2011) 117 (13): 3613–3616.

https://doi.org/10.1182/blood-2010-12-324665

Published: 2011

Includes: Supplemental data

Journal Articles

Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis

Bruno Paiva, María-Belén Vidriales, Jose J. Perez, Maria-Consuelo López-Berges, Ramón García-Sanz, Enrique M. Ocio, Rebeca Garcia, Alfonso Garcia de Coca, Emilia Pardal, Magdalena Sierra, Jose Hernández, Natalia de las Heras, Josefina Galende, Jose Maria Alonso, Abelardo Bárez, María-Victoria Mateos, Jesus F San Miguel

Blood (2010) 116 (21): 4051.

https://doi.org/10.1182/blood.V116.21.4051.4051

Published: 2010

NARROW

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM)

Immune Predictors of Response to Pembrolizumab Monotherapy As Consolidation in Multiple Myeloma Patients: Results of the GEM-Pembresid Clinical Trial

Peripheral Blood Analysis By Flow Cytometry for the Diagnosis of Type I Chronic Myelomonocytic Leukemia

Next Generation Flow (NGF) for High Sensitive Detection of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)

PD-1 and PD-L1 Are Overexpressed in the "Intermediate CD14+CD16+" and "Non Classical CD14lowCD16+" but Not in the "Classical CD14+CD16-" Monocytes in the Peripheral Blood of Chronic Myelomonocytic Leukemia

The cellular origin and malignant transformation of Waldenström macroglobulinemia

Whole Bone Marrow (BM) Immunophenotypic Profiling for the Identification of Newly Diagnosed Symptomatic Multiple Myeloma (MM) Patients with an MGUS-Like Signature Associated with Long-Term Disease Control (LTDC)

Biological and Clinical Significance of CD81 Expression by Clonal Plasma Cells in High-Risk Smoldering and Symptomatic Multiple Myeloma (MM) Patients,

Multiparameter Flow Cytometry (MFC) Evaluation of Plasma Cell (PC) DNA Ploidy Status and Proliferative Rate in 595 Multiple Myeloma (MM) Patients (pts) Included in the Spanish GEM2000 and GEM2005<65years Trials: Clinical Value and Biological Insights,

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

Utility of Multiparameter Flow Cytometry Immunophenotypic Studies In Patients with Systemic Light Chain (AL) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only